PMA · Approved
Recalled · 2010Euflexxa (1% Sodium Hyaluronate)
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Ferring Pharmaceuticals, Inc. · MOZ Acid, Hyaluronic, Intraarticular
Approved on Dec 3, 2004 through premarket approval, which rests on the device’s own clinical evidence after a 1,312-day review. It has been recalled once.
- Decided
- Dec 3, 2004
- Review
- 1,312 days
- Class
- Class III
- Product code
- MOZ
- Recalls
- 1
PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.
P010029 has 40 supplements since 2005: changes to the approved device, its labelling or its manufacturing, each approved separately.
PMA supplements approved per year
View FIG. 1 as a table
| Year | Supplements approved |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 1 |
Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MOZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
Does it have a predicate?
PMA decisions do not claim a predicate device.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Apr 16, 2010 | Not classified | Z-1635-2010 | Process control | Out of Specification results for molecular weight or viscosity through the established expiration date. |
No ancestor or descendant has a Class I recall.
How does its category compare?
All MOZ devicesMOZ Acid, Hyaluronic, Intraarticular: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · MOZ
13in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MOZ
Too few MOZ 510(k)s in any year since 2007 to give a median.
Recalls per year · MOZ
1in 2017
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MOZ
176in 2025
MAUDE reports naming product code MOZ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 6 | — | 0 | 132 |
| 2008 | 5 | — | 0 | 222 |
| 2009 | 10 | — | 0 | 314 |
| 2010 | 7 | — | 1 | 323 |
| 2011 | 9 | — | 0 | 386 |
| 2012 | 12 | — | 0 | 462 |
| 2013 | 10 | — | 0 | 637 |
| 2014 | 28 | — | 0 | 340 |
| 2015 | 21 | — | 0 | 293 |
| 2016 | 21 | — | 0 | 313 |
| 2017 | 16 | — | 1 | 506 |
| 2018 | 21 | — | 0 | 1,099 |
| 2019 | 12 | — | 0 | 567 |
| 2020 | 22 | — | 0 | 441 |
| 2021 | 20 | — | 0 | 375 |
| 2022 | 20 | — | 0 | 305 |
| 2023 | 13 | — | 0 | 470 |
| 2024 | 11 | — | 0 | 292 |
| 2025 | 13 | — | 0 | 176 |
| 2026 | 8 | — | 0 | — |
https://510kreport.com/device/P010029 · printed Nov 6, 2026
Cite this page
510(k) Report. “P010029: Euflexxa (1% Sodium Hyaluronate).” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P010029
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Page last updated Nov 3, 2026